Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker INSM · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants Wit… NCT07234032 · Pulmonary Hypertension, Interstitial Lung Disease Treprostinil Palmitil Inhalation Powder, Placebo | INSM Insmed Incorporated | Phase 3 | Recruiting | 344 | Jan 22, 2031 | Registry ↗ |
| Nov 9, 2026 | A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Particip… NCT07765706 · Healthy Volunteers INS1033, Placebo | INSM Insmed Incorporated | Phase 1 | Recruiting | 116 | Mar 22, 2027 | Registry ↗ |
| Nov 9, 2026 | A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil… NCT07643155 · Hepatic Impairment Treprostinil Palmitil Inhalation Powder | INSM Insmed Incorporated | Phase 1 | Recruiting | 30 | Feb 7, 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Witho… NCT06013241 · Chronic Rhinosinusitis Without Nasal Polyps Brensocatib, Placebo | INSM Insmed Incorporated | Phase 2 | Completed | 288 | Sep 30, 2025 | Registry ↗ |
| Nov 2, 2026 | A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Part… NCT07805785 · Progressive Pulmonary Fibrosis, Interstitial Lung Disease Treprostinil Palmitil Inhalation Powder, Placebo | INSM Insmed Incorporated | Phase 3 | Recruiting was not yet recruiting | 800 | Aug 31, 2030 | Registry ↗ |
| Oct 26, 2026 | Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pu… NCT07179380 · Pulmonary Hypertension, Interstitial Lung Disease Treprostinil Palmitil Inhalation Powder, Placebo | INSM Insmed Incorporated | Phase 3 | Recruiting | 344 | Dec 30, 2028 | Registry ↗ |
| Oct 20, 2026 | An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hyperte… NCT05649748 · Pulmonary Arterial Hypertension Treprostinil Palmitil, Placebo | INSM Insmed Incorporated | Phase 2/3 | Active, not recruiting | 91 | Dec 31, 2026 | Registry ↗ |
| Oct 16, 2026 | An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants… NCT06939647 · Pulmonary Arterial Hypertension, Pulmonary Hypertension, In… Treprostinil Palmitil | INSM Insmed Incorporated | — | Available | — | — | Registry ↗ |
| Oct 13, 2026 | A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (… NCT07481981 · Pulmonary Arterial Hypertension Treprostinil Palmitil Inhalation Powder, Placebo | INSM Insmed Incorporated | Phase 3 | Recruiting | 344 | Dec 28, 2028 | Registry ↗ |
| Oct 5, 2026 | A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK)… NCT07859007 · Healthy Volunteers Brensocatib, Midazolam | INSM Insmed Incorporated | Phase 1 | Not yet recruiting | 26 | Nov 25, 2026 | Registry ↗ |
| Sep 11, 2026 | Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis) NCT06101823 · Atopic Dermatitis OpSCF, Placebo | INSM Insmed Incorporated | Phase 2 | Completed | 50 | Sep 3, 2024 | Registry ↗ |
| Jun 29, 2026 | A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Su… NCT06685835 · Hidradenitis Suppurativa Brensocatib, Placebo | INSM Insmed Incorporated | Phase 2 | Terminated | 214 | Feb 12, 2026 | Registry ↗ |
| Apr 23, 2026 | An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Ass… NCT05649722 · Pulmonary Hypertension, Interstitial Lung Disease Treprostinil Palmitil Inhalation Powder, Placebo | INSM Insmed Incorporated | Phase 2/3 | Completed | 31 | Apr 1, 2026 | Registry ↗ |
| Mar 30, 2026 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation P… NCT05147805 · Pulmonary Arterial Hypertension Treprostinil Palmitil, Placebo | INSM Insmed Incorporated | Phase 2 | Completed | 102 | Mar 27, 2025 | Registry ↗ |
| Mar 12, 2026 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults W… NCT05090904 · Cystic Fibrosis Brensocatib, Placebo | INSM Insmed Incorporated | Phase 2 | Completed | 29 | Nov 1, 2022 | Registry ↗ |
| Feb 3, 2026 | Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculou… NCT04677569 · Mycobacterium Infections, Nontuberculous ALIS, Azithromycin | INSM Insmed Incorporated | Phase 3 | Completed | 425 | Nov 21, 2025 | Registry ↗ |
| Dec 16, 2025 | A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cy… NCT04594369 · Non-Cystic Fibrosis Bronchiectasis Brensocatib 10 mg, Brensocatib 25 mg | INSM Insmed Incorporated | Phase 3 | Completed | 1,767 | Oct 28, 2024 | Registry ↗ |
| Nov 21, 2025 | A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprost… NCT07102316 · Healthy Volunteers TPIP F2, TPIP F3 | INSM Insmed Incorporated | Phase 1 | Completed | 42 | Oct 25, 2025 | Registry ↗ |
| Nov 4, 2025 | An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiect… NCT05344508 · Non-Cystic Fibrosis Bronchiectasis Brensocatib | INSM Insmed Incorporated | — | Approved for marketing | — | — | Registry ↗ |
| Mar 17, 2025 | A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Parti… NCT05176951 · Pulmonary Hypertension Treprostinil Palmitil, Placebo | INSM Insmed Incorporated | Phase 2 | Completed | 39 | Mar 14, 2024 | Registry ↗ |
| Jun 28, 2024 | Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial L… NCT04677543 · Mycobacterium Infections, Nontuberculous ALIS, Azithromycin | INSM Insmed Incorporated | Phase 3 | Completed | 99 | May 9, 2023 | Registry ↗ |
| Jun 13, 2024 | A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Table… NCT06344728 · Healthy Participants Brensocatib Oral Solution, Brensocatib Oral Tablet | INSM Insmed Incorporated | Phase 1 | Completed | 24 | May 24, 2024 | Registry ↗ |
| Feb 2, 2024 | Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Pa… NCT06238856 · Cystic Fibrosis SLIT™ Amikacin, Placebo | INSM Insmed Incorporated | Phase 1 | Completed | 18 | Feb 8, 2005 | Registry ↗ |
| Jan 22, 2024 | A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in… NCT06178783 · Healthy Volunteers Brensocatib | INSM Insmed Incorporated | Phase 1 | Completed | 20 | Jan 4, 2024 | Registry ↗ |
| Jan 5, 2024 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyv… NCT06193031 · Healthy Volunteers C16TR, Placebo | INSM Insmed Incorporated | Phase 1 | Completed | 24 | Dec 18, 2015 | Registry ↗ |
| Dec 11, 2023 | A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmaco… NCT05965570 · Healthy Volunteers Brensocatib, Clarithromycin | INSM Insmed Incorporated | Phase 1 | Completed | 22 | Sep 22, 2023 | Registry ↗ |
| Oct 19, 2023 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalati… NCT06091579 · Healthy Volunteers Treprostinil Palmitil Inhalation Powder, Placebo | INSM Insmed Incorporated | Phase 1 | Completed | 42 | Jan 12, 2021 | Registry ↗ |
| Sep 22, 2023 | A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH) NCT04791514 · Pulmonary Arterial Hypertension Treprostinil Palmitil | INSM Insmed Incorporated | Phase 2 | Terminated | 1 | Aug 26, 2022 | Registry ↗ |
| Aug 21, 2023 | A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Partici… NCT05999942 · Healthy Volunteers Liposomal Amikacin for Inhalation | INSM Insmed Incorporated | Phase 1 | Completed | 6 | Jun 29, 2004 | Registry ↗ |
| Aug 21, 2023 | A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or… NCT05826574 · Healthy Volunteers Brensocatib, Rifampin | INSM Insmed Incorporated | Phase 1 | Completed | 32 | Jul 16, 2023 | Registry ↗ |
| Jul 19, 2023 | A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Partici… NCT05517525 · Hepatic Impairment Brensocatib | INSM Insmed Incorporated | Phase 1 | Completed | 30 | Jun 1, 2023 | Registry ↗ |
| Jul 3, 2023 | A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Ca… NCT05927597 · Healthy Volunteers INS1007, Placebo | INSM Insmed Incorporated | Phase 1 | Completed | 82 | Aug 1, 2019 | Registry ↗ |
| Apr 18, 2023 | A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal… NCT05673603 · Renal Impairment Brensocatib | INSM Insmed Incorporated | Phase 1 | Completed | 28 | Feb 14, 2023 | Registry ↗ |
| Mar 27, 2023 | A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants NCT05355935 · Healthy Volunteer Brensocatib, Moxifloxacin | INSM Insmed Incorporated | Phase 1 | Completed | 48 | Oct 7, 2022 | Registry ↗ |
| Mar 27, 2023 | Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis NCT03218917 · Non-Cystic Fibrosis Bronchiectasis Brensocatib 10 mg, Brensocatib 25 mg | INSM Insmed Incorporated | Phase 2 | Completed | 256 | Dec 12, 2019 | Registry ↗ |
| Mar 23, 2023 | A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral A… NCT05652257 · Healthy Volunteers [14C]-brensocatib | INSM Insmed Incorporated | Phase 1 | Completed | 7 | Sep 14, 2021 | Registry ↗ |
| Jan 6, 2022 | Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insul… NCT00577577 · Myotonic Dystrophy Type 1 rhIGF-I/rhIGFBP-3, placebo | INSM Insmed Incorporated | Phase 2 | Completed | 69 | Dec 29, 2008 | Registry ↗ |
| Jul 30, 2020 | Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase NCT03905642 · Cystic Fibrosis Arikayce™ | INSM Insmed Incorporated | Phase 2 | Completed | 49 | Nov 2, 2010 | Registry ↗ |
| Jul 30, 2020 | Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (AR… NCT00777296 · Cystic Fibrosis ARIKACE™, Placebo | INSM Insmed Incorporated | Phase 1/2 | Completed | 66 | Feb 27, 2008 | Registry ↗ |
| Jun 17, 2020 | Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic… NCT01316276 · Cystic Fibrosis Liposomal amikacin for inhalation | INSM Insmed Incorporated | Phase 3 | Completed | 206 | Jul 16, 2015 | Registry ↗ |
| Jun 16, 2020 | Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections NCT01315678 · Pseudomonas Aeruginosa Infection Liposomal amikacin for inhalation (Arikayce™) using the PAR… | INSM Insmed Incorporated | Phase 3 | Completed | 302 | Jun 2013 | Registry ↗ |
| May 7, 2020 | Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen A… NCT02344004 · Mycobacterium Infections, Nontuberculous LAI (Liposomal Amikacin for Inhalation) 590 mg | INSM Insmed Incorporated | Phase 3 | Completed | 336 | Jul 3, 2018 | Registry ↗ |
| Feb 10, 2020 | Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Particip… NCT02628600 · NTM Lung Infection Due to MAC LAI 590 mg, Multi-drug regimen | INSM Insmed Incorporated | Phase 3 | Completed | 163 | Oct 17, 2018 | Registry ↗ |
| Aug 21, 2019 | Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria NCT01315236 · Mycobacterium Infections, Nontuberculous Liposomal amikacin for inhalation (LAI), placebo | INSM Insmed Incorporated | Phase 2 | Completed | 90 | Aug 18, 2014 | Registry ↗ |
| Jul 10, 2019 | Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chro… NCT00775138 · Bronchiectasis 280 mg Arikayce™, Matching Placebo for Cohort 1 | INSM Insmed Incorporated | Phase 2 | Completed | 64 | May 11, 2009 | Registry ↗ |
| Jun 4, 2019 | Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Ps… NCT00558844 · Cystic Fibrosis Arikayce™ 560 mg, Placebo for 560 mg | INSM Insmed Incorporated | Phase 1/2 | Completed | 41 | Jun 2009 | Registry ↗ |
| Jul 31, 2018 | Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa NCT01315691 · Cystic Fibrosis Liposomal amikacin for inhalation, Placebo for liposomal am… | INSM Insmed Incorporated | Phase 3 | Withdrawn | 0 | — | Registry ↗ |
| Aug 1, 2017 | Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung NCT00102531 · Osteosarcoma Metastatic Cisplatin liposomal | INSM Insmed Incorporated | Phase 1/2 | Completed | 19 | Mar 2008 | Registry ↗ |
48 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:18 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances